TARS
Tarsus Pharmaceuticals, Inc.
$62.26
-1.22
(-1.92%)
Mkt Cap
2.68B
Volume
249,903
52W Range
38.51-85.25
Sector
Healthcare
Beta
0.53
EPS (TTM)
-1.14
P/E Ratio
-51.51
Revenue (TTM)
535.08M
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 451.36M | 182.95M | 17.45M | 25.82M | 57.03M | 0 | 0 | 0 |
| Net Income | (66.42M) | (115.55M) | (135.89M) | (62.09M) | (13.83M) | (26.81M) | (4.67M) | (1.32M) |
| EPS | -1.59 | -3.07 | -4.62 | -2.52 | -0.67 | -1.32 | -0.24 | -0.31 |
| Free Cash Flow | (22.31M) | (84.59M) | (123.00M) | (49.54M) | 3.16M | (21.59M) | (3.85M) | (1.19M) |
| FCF / Share | -0.53 | -2.25 | -4.19 | -2.01 | 0.15 | -1.06 | -0.20 | -0.28 |
| Operating CF | (12.45M) | (83.03M) | (117.49M) | (49.03M) | 3.75M | (21.14M) | (3.67M) | (1.18M) |
| Total Assets | 562.16M | 376.99M | 265.49M | 227.86M | 178.91M | 171.97M | 58.32M | 2.39M |
| Total Debt | 93.64M | 72.45M | 30.22M | 20.21M | 1.89M | 831,000 | 164,000 | 0 |
| Cash & Equiv | 183.64M | 94.82M | 224.95M | 71.66M | 171.33M | 168.13M | 57.95M | 2.35M |
| Book Value | 343.43M | 224.53M | 196.99M | 192.90M | 166.73M | 165.98M | (6.00M) | (1.35M) |
| Return on Equity | -0.19 | -0.51 | -0.69 | -0.32 | -0.08 | -0.16 | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 162.05M | 151.67M | 118.70M | 102.66M | 78.33M | 66.41M | 48.12M | 40.81M | 27.61M | 13.08M | 1.87M | 0 |
| Net Income | (6.97M) | (8.37M) | (12.59M) | (20.34M) | (25.12M) | (23.11M) | (23.42M) | (33.29M) | (35.73M) | (41.90M) | (39.15M) | (31.42M) |
| EPS | -0.16 | -0.20 | -0.30 | -0.48 | -0.64 | -0.60 | -0.61 | -0.88 | -1.01 | -1.31 | -1.28 | -1.17 |
| Free Cash Flow | (30.47M) | 12.97M | 16.35M | (30.39M) | (21.24M) | (27.25M) | (8.93M) | (15.44M) | (37.96M) | (39.34M) | (36.74M) | (24.61M) |
| FCF / Share | -0.71 | 0.30 | 0.38 | -0.72 | -0.54 | -0.71 | -0.23 | -0.41 | -1.08 | -1.23 | -1.20 | -0.92 |
| Operating CF | (24.65M) | 19.33M | 18.26M | (29.39M) | (20.65M) | (22.18M) | (8.65M) | (14.40M) | (37.79M) | (39.34M) | (32.36M) | (23.83M) |
| Total Assets | 581.13M | 562.16M | 534.56M | 494.99M | 500.75M | 376.99M | 376.30M | 376.84M | 349.28M | 265.49M | 268.33M | 188.93M |
| Total Debt | 88.68M | 93.64M | 82.51M | 72.45M | 72.37M | 72.45M | 72.34M | 72.18M | 30.52M | 30.22M | 30.13M | 25.04M |
| Cash & Equiv | 102.19M | 183.64M | 112.72M | 96.65M | 175.79M | 94.82M | 176.21M | 181.09M | 193.71M | 224.95M | 226.67M | 106.77M |
| Book Value | 348.95M | 343.43M | 335.08M | 332.61M | 342.46M | 224.53M | 237.48M | 252.25M | 275.21M | 196.99M | 213.66M | 147.73M |
| Return on Equity | -0.02 | -0.02 | -0.04 | -0.06 | -0.07 | -0.10 | -0.10 | -0.13 | -0.13 | -0.21 | -0.18 | -0.21 |
TARS News
Tarsus Q1 Review: Strong Earnings, But Wall Street Wanted A Guidance Raise
Tarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million Americans
Tarsus Pharmaceuticals, Inc. (TARS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Tarsus to Participate in Upcoming Investor Conferences
Tarsus Pharmaceuticals, Inc. (TARS) Q1 2026 Earnings Call Transcript
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Beats Revenue Estimates
Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements
Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026
Calamos Advisors LLC Makes New $2.82 Million Investment in Tarsus Pharmaceuticals, Inc. $TARS
Tarsus Pharmaceuticals: Marketing Spend Bears Fruit, Pipeline Progresses